Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that develops antibody treatments for chronic skin and inflammatory diseases. Its goal is to offer therapies that need only infrequent dosing, potentially once or twice a year, while maintaining strong disease control.

Its lead candidate, ORKA-001, is an antibody targeting IL-23p19 that is engineered for an extended half-life and is being studied in plaque psoriasis. A second program, ORKA-002, targets IL-17A and IL-17F and is being developed for psoriasis, psoriatic arthritis and other conditions such as hidradenitis suppurativa.

Oruka became a public company in 2024 through a merger with ARCA biopharma, and its common stock trades on the Nasdaq.